新药周观点：医保谈判即将启动，国内企业多个创新药品种有望参与

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector, indicating a positive outlook compared to the market [4]. Core Insights - The report highlights that the upcoming negotiations for the National Medical Insurance (NMI) drug list are expected to involve several innovative drugs from domestic companies, with anticipation for favorable outcomes [2][19]. - A total of 4 new drugs or new indications were approved for market launch, 32 new drugs received Investigational New Drug (IND) approvals, 66 new INDs were accepted, and 9 New Drug Applications (NDAs) were accepted during the week [27][30]. Summary by Sections New Drug Market Review - From September 23 to September 27, 2024, the top five companies in the new drug sector by stock price increase were: Kexin Pharmaceutical (39.87%), Rongchang Bio (32.59%), Deqi Pharmaceutical (23.64%), Yiming Oncology (21.36%), and Kain Technology (20.54%). The top five companies with the largest declines were: Yongtai Bio (-9.86%), Youzhiyou (-3.90%), Dongyao Pharmaceutical (-2.50%), Chuangsheng Group (-1.92%), and Fuhong Hanlin (-1.30%) [1][15]. New Drug Approval and Acceptance - The report details that four new drugs or new indications were approved for market launch, with significant developments in clinical trials, including positive results from the HORIZON Phase 3 trial for the OX40-targeting monoclonal antibody rocatinlimab [2][5]. - Notable approvals include the acceptance of the NDA for the recombinant anti-IL-23p19 antibody by Innovent Biologics and the strategic collaboration between Sanofi and Tianjing Bio for the development of a novel CD73 antibody [2][5]. Focus on Domestic and Overseas New Drugs - The report emphasizes the importance of the upcoming NMI negotiations, with several domestic companies such as Heng Rui Pharmaceutical, Innovent Biologics, and others having new products in the negotiation process, which could lead to significant market opportunities [2][19]. - The report also notes the ongoing clinical advancements in both domestic and overseas markets, with a focus on innovative therapies and their potential impact on patient care [5].